Select Your Region
Americas
Europe
Africa
Global
Find participating medical centers and current study status in each of them
Find participating medical centers
-
Home
-
Clinical Study Finder
- GENERATION HD1
A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington’s Disease
A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease
Neurodegenerative Disorder Huntington Disease (HD)
Study results
LPS BN40423 GENERATION HD1 Final Results September 2023 English
(PDF, 1.2 MB)
LPS BN40423 GENERATION HD1 Final Results July 2023 Russia Russian
(PDF, 0.7 MB)
LPS BN40423 GENERATION HD1 Final Results November 2023 France French
(PDF, 1.7 MB)
LPS BN40423 GENERATION HD1 Final Results November 2023 Japan Japanese
(PDF, 1.8 MB)
LPS BN40423 GENERATION HD1 Final Results September 2023 Argentina Spanish
(PDF, 1.4 MB)
LPS BN40423 GENERATION HD1 Final Results September 2023 Austria German
(PDF, 2.0 MB)
LPS BN40423 GENERATION HD1 Final Results September 2023 Chile Spanish
(PDF, 1.2 MB)
LPS BN40423 GENERATION HD1 Final Results September 2023 Germany German
(PDF, 1.3 MB)
LPS BN40423 GENERATION HD1 Final Results September 2023 Italy Italian
(PDF, 1.1 MB)
LPS BN40423 GENERATION HD1 Final Results September 2023 Netherlands Dutch
(PDF, 1.0 MB)
LPS BN40423 GENERATION HD1 Final Results September 2023 Poland Polish
(PDF, 1.1 MB)
LPS BN40423 GENERATION HD1 Final Results September 2023 Spain Spanish
(PDF, 1.1 MB)
LPS BN40423 GENERATION HD1 Final Results September 2023 Switzerland French
(PDF, 1.8 MB)
LPS BN40423 GENERATION HD1 Final Results September 2023 Denmark Danish
(PDF, 1.2 MB)
Explore related studies
For the latest version of this information please go to www.forpatients.roche.com